BIO Stock: Price, Earnings History and SEC Filings
Bio-Rad Laboratories, Inc. (BIO) last traded at $372.18, down 3.18% on the latest session and down 1.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $2.62 against an analyst estimate of $2.34, a beat of 12.0%.
$372.18 -3.18%
1 month-1.46%
52-week high$396.23
52-week low$236.73
Volume183,084
ExchangeNYSE
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
BIO earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $2.62 | $2.34 | +11.97% |
| Mar 2026 | Apr 30, 2026 | $1.89 | $2.77 | -31.77% |
| Dec 2025 | Feb 12, 2026 | $2.51 | $2.57 | -2.33% |
| Sep 2025 | Oct 29, 2025 | $2.26 | $2.30 | -1.74% |
BIO beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for BIO
SEC filing data is not available right now. You can search for BIO on SEC EDGAR.
BIO news
- Bio Rad Laboratories (BIO) Stock Looks Fully Valued After 49% Five Year FallOct 31, 2026 · finance.yahoo.com
- Bio Rad Laboratories (BIO) Stock Dropped, What Is Behind The Fresh Attention?Oct 31, 2026 · finance.yahoo.com
- Nathan Fielder Meets Ryan ElHosseiny: The Science Behind “The Strip Club” and “Who’s on First” in You Can See EverythingOct 30, 2026 · finance.yahoo.com
- Will TXG Stock Ever Get Back To Its Old High?Oct 30, 2026 · trefis.com
- Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare ConferenceOct 29, 2026 · finance.yahoo.com
- Reaction Monitoring - Global Strategic Business Report: Secure Share of the $2 Billion 2030 Market as Tariffs Reshape Danaher, Bruker, Bio-Rad, Waters, and Shimadzu StrategiesOct 29, 2026 · finance.yahoo.com
- Long-Read Full-Length cDNA Sequencing Global Market Report 2026 | Capitalize on 18.9% CAGR and Single-Cell Demand With PacBio, Oxford Nanopore, 10x Genomics and QIAGENOct 29, 2026 · finance.yahoo.com
- Microarray Scanners - Global Strategic Business Report 2026: Capitalize on $1.6 Billion Industry Revenue by 2032 | Thermo Fisher Scientific, Agilent Technologies, Illumina, and Bio-Rad Laboratories DominateOct 28, 2026 · finance.yahoo.com
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. (BIO) is a US-listed public company on NYSE.